Lipoxin A4 and platelet activating factor are involved in E. coli or LPS-induced lung inflammation in CFTR-deficient mice

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Wu, Haiya ^a   Yang, Jun ^b   Su, Emily M ^c   Li, Ling ^a   Zhao, Caiqi ^a   Yang, Xi ^a   Gao, Zhaowei ^a   Pan, Mengyao ^a   Sun, Peiyu ^a   Sun, Wei ^a   Jiang, Yiyi ^a   Su, Xiao ^a,c  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; LIPOPOLYSACCHARIDE; LIPOXIN A; MACROPHAGE MIGRATION INHIBITION FACTOR; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; THROMBOCYTE ACTIVATING FACTOR; CXCL2 CHEMOKINE; CXCL2 PROTEIN, MOUSE; LIPOXIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LUNG LAVAGE; MASS SPECTROMETRY; MOUSE; NEUTROPHIL; NEUTROPHIL COUNT; NONHUMAN; PNEUMONIA; THROMBOCYTOPENIA; WILD TYPE; ANIMAL; BLOOD; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MOUSE; DEFICIENCY; GENETICS; METABOLISM; MUTATION; PATHOLOGY; THROMBOCYTE COUNT;

ANIMALS; BRONCHOALVEOLAR LAVAGE; CHEMOKINE CXCL2; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ESCHERICHIA COLI; LIPOPOLYSACCHARIDES; LIPOXINS; MICE, INBRED CFTR; MUTATION; P-SELECTIN; PLATELET ACTIVATING FACTOR; PLATELET COUNT; PNEUMONIA; THROMBOCYTOPENIA;

EID: 84899797428     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093003     Document Type: Article

References (30)

1. Su X, Looney MR, Su HE, Lee JW, Song Y, et al. (2011) Role of CFTR expressed by neutrophils in modulating acute lung inflammation and injury in mice. Inflamm Res 60: 619-632.
2. Zhao C, Su EM, Yang X, Gao Z, Li L, et al. (2013) Important Role of Platelets in Modulating Endotoxin-Induced Lung Inflammation in CFTR-Deficient Mice. PLoS One 8: e82683.
3. Matthay MA, Su X (2007) Pulmonary barriers to pneumonia and sepsis. Nat Med 13: 780-781. (Pubitemid 47038178)
4. Karp CL, Flick LM, Park KW, Softic S, Greer TM, et al. (2004) Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 5: 388-392. (Pubitemid 38500087)
5. Serhan CN, Chiang N, Van Dyke TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8: 349-361. (Pubitemid 351595216)
6. Serhan CN, Sheppard KA (1990) Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J Clin Invest 85: 772-780. (Pubitemid 20087480)
7. O'Sullivan BP, Linden MD, Frelinger AL, 3rd, Barnard MR, Spencer-Manzon M, et al. (2005) Platelet activation in cystic fibrosis. Blood 105: 4635-4641. (Pubitemid 40807282)
8. Schwarz KB, Rosensweig J, Sharma S, Jones L, Durant M, et al. (2003) Plasma markers of platelet activation in cystic fibrosis liver and lung disease. J Pediatr Gastroenterol Nutr 37: 187-191. (Pubitemid 39274547)
9. Dalli J, Rosignoli G, Hayhoe RP, Edelman A, Perretti M (2010) CFTR inhibition provokes an inflammatory response associated with an imbalance of the annexin A1 pathway. Am J Pathol 177: 176-186.
10. Perez A, Issler AC, Cotton CU, Kelley TJ, Verkman AS, et al. (2007) CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 292: L383-395.
11. Lam FW, Burns AR, Smith CW, Rumbaut RE (2011) Platelets enhance neutrophil transendothelial migration via P-selectin glycoprotein ligand-1. Am J Physiol Heart Circ Physiol 300: H468-475.
12. Mitsios JV, Vini MP, Stengel D, Ninio E, Tselepis AD (2006) Human platelets secrete the plasma type of platelet-activating factor acetylhydrolase primarily associated with microparticles. Arterioscler Thromb Vasc Biol 26: 1907-1913. (Pubitemid 44305349)
13. Yang J, Xu J, Chen X, Zhang Y, Jiang X, et al. (2010) Decrease of plasma platelet-activating factor acetylhydrolase activity in lipopolysaccharide induced mongolian gerbil sepsis model. PLoS One 5: e9190.
14. Su X, Looney M, Robriquet L, Fang X, Matthay MA (2004) Direct visual instillation as a method for efficient delivery of fluid into the distal airspaces of anesthetized mice. Exp Lung Res 30: 479-493. (Pubitemid 39096096)
15. Su X, Matthay MA, Malik AB (2010) Requisite role of the cholinergic alpha7 nicotinic acetylcholine receptor pathway in suppressing Gram-negative sepsis-induced acute lung inflammatory injury. J Immunol 184: 401-410.
16. Su X, Matthay MA (2009) Role of protease activated receptor 2 in experimental acute lung injury and lung fibrosis. Anat Rec (Hoboken) 292: 580-586.
17. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, et al. (2009) Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 119: 3450-3461.
18. Matute-Bello G, Frevert CW, Kajikawa O, Skerrett SJ, Goodman RB, et al. (2001) Septic shock and acute lung injury in rabbits with peritonitis: failure of the neutrophil response to localized infection. Am J Respir Crit Care Med 163: 234-243. (Pubitemid 32095275)
19. Owen JS, Wykle RL, Samuel MP, Thomas MJ (2005) An improved assay for platelet-activating factor using HPLC-tandem mass spectrometry. J Lipid Res 46: 373-382. (Pubitemid 40271102)
20. Su X (2012) Leading neutrophils to the alveoli: who is the guider? Am J Respir Crit Care Med 186: 472-473.
21. Jehle R, Schlame M, Buttner C, Frey B, Sinha P, et al. (2001) Platelet-activating factor (PAF)-acetylhydrolase and PAF-like compounds in the lung: effects of hyperoxia. Biochim Biophys Acta 1532: 60-66. (Pubitemid 32553948)
22. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM (2002) The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 30: S294-301. (Pubitemid 34508006)
23. Kell PJ, Creer MH, Crown KN, Wirsig K, McHowat J (2003) Inhibition of platelet-activating factor (PAF) acetylhydrolase by methyl arachidonyl fluor-ophosphonate potentiates PAF synthesis in thrombin-stimulated human coronary artery endothelial cells. J Pharmacol Exp Ther 307: 1163-1170. (Pubitemid 37494238)
24. Ciabattoni G, Davi G, Collura M, Iapichino L, Pardo F, et al. (2000) In vivo lipid peroxidation and platelet activation in cystic fibrosis. Am J Respir Crit Care Med 162: 1195-1201.
25. Dhooghe B, Noel S, Huaux F, Leal T (2013) Lung inflammation in cystic fibrosis: Pathogenesis and novel therapies. Clin Biochem.
26. Zhou Y, Song K, Painter RG, Aiken M, Reiser J, et al. (2013) Cystic fibrosis transmembrane conductance regulator recruitment to phagosomes in neutrophils. J Innate Immun 5: 219-230.
27. Painter RG, Valentine VG, Lanson NA, Jr., Leidal K, Zhang Q, et al. (2006) CFTR Expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry 45: 10260-10269. (Pubitemid 44384801)
28. Makristathis A, Stauffer F, Feistauer SM, Georgopoulos A (1993) Bacteria induce release of platelet-activating factor (PAF) from polymorphonuclear neutrophil granulocytes: possible role for PAF in pathogenesis of experimentally induced bacterial pneumonia. Infect Immun 61: 1996-2002. (Pubitemid 23145904)
29. Rabinovici R, Esser KM, Lysko PG, Yue TL, Griswold DE, et al. (1991) Priming by platelet-activating factor of endotoxin-induced lung injury and cardiovascular shock. Circ Res 69: 12-25.
30. Beijer L, Botting J, Crook P, Oyekan AO, Page CP, et al. (1987) The involvement of platelet activating factor in endotoxin-induced pulmonary platelet recruitment in the guinea-pig. Br J Pharmacol 92: 803-808. (Pubitemid 18014930)